Core Viewpoint - Northstrive Biosciences Inc. is advancing its obesity treatment candidates, EL-22 and EL-32, focusing on fat loss while preserving muscle mass, with plans for regulatory meetings and clinical trials in 2025 [1][4][6]. Group 1: EL-22 Development - Northstrive is preparing for a Type B pre-IND meeting with the FDA in Q2 2025, having completed necessary translations and compiled data from its South Korean partner [2][3]. - EL-22 is a novel engineered probiotic targeting the myostatin pathway, showing significant improvements in preclinical studies and safety in a Phase 1 trial in South Korea [3][4]. - The company aims to file an Investigational New Drug application in 2025 to initiate clinical trials combining EL-22 with GLP-1 receptor agonists for obesity treatment [4][8]. Group 2: EL-32 Development - Northstrive has engaged a leading CRO for a preclinical study of EL-32, which expresses dual myostatin and activin-A inhibitors, focusing on glycemic control and body composition in diet-induced obese mice [5][8]. - The study will evaluate EL-32 both as a monotherapy and in combination with the GLP-1 receptor agonist semaglutide [5]. Group 3: Upcoming Presentation - Northstrive will present its obesity drug candidates at the UCLA Obesity Symposium on February 7, 2025, highlighting the muscle-preserving therapeutic potential of its myostatin-engineered probiotics [6]. Group 4: Company Overview - Northstrive Biosciences Inc. is a biopharmaceutical company under PMGC Holdings Inc., focusing on innovative treatments for obesity while preserving muscle mass during weight loss therapies [7][8].
Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1